MCMarianne Chapleau

Marianne Chapleau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marianne Chapleau has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of FDG‐PET with co‐pathologies in autopsy‐proven AD

    by Marianne Chapleau, Nidhi Mundada, Salvatore Spina, William W. Seeley, Lea T. Grinberg, Daniel Schonhaut, Howard J. Rosen, Joel H. Kramer, Bruce L Miller, Renaud La Joie, et al.

    Background: The presence of multiple pathologies is the rule and not the exception in Alzheimer’s disease (AD). The goal of this study was to assess whether 18F fluorodeoxyglucose (FDG) PET can provide information about the presence of non‐AD pathologies in autopsy‐proven AD patients.Method: Our cohort included 55 patients with antemortem FDG‐PET and autopsy‐proven intermediate/high ADNC from the UCSF Neurodegenerative Diseases Brain Bank. All patients underwent FDG‐PET. Standardized uptake value ratio (SUVR) images were computed using the pons as reference region. W‐maps (adjusted Z‐score maps) were created, comparing each patient to a group of 187 controls (age range: 20‐96, 40% males). Voxel‐wise correlations were computed to verify the unique contribution of each neuropathology to cerebral hypometabolism, while controlling for age, sex, time between FDG‐PET scan and death, scanner type, Thal and Braak staging, and the presence of all other co‐pathologies. Associations between SUVR values in specific region of interests (ROIs) were also assessed. The ROIs included were the following: Landau AD ROI for AD pathology, Cingulate Island Sign (CIS) for Lewy body disease, Inferior/Medial Temporal Lobe (IMT) and IMT/Frontal Supraorbital (IMT/FSO) ratios for limbic‐predominant age‐related TDP43 encephalopathy neuropathologic change (LATE‐NC).Result: Mean age was 63.8 ± 10.5, mean time between FDG and death was 6.2 ± 2.8, and mean MMSE was 21.1 ± 7.1 at the time of PET (Table 1). Group averaged W‐map showed the typical temporo‐parietal AD pattern; hypometabolism in these regions was associated with higher Thal phase and Braak stage (Figure 1). Lewy body disease (LBD), argyrophilic grain disease (AGD), aging‐related tau astrogliopathy (ARTAG), cerebral amyloid angiopathy (CAA) and vascular brain injury (VBI) were associated with hypometabolism in small discrete regional clusters (Figure 2). The Landau AD ROI was associated with both Thal (rs = ‐0.325, p = .015) and Braak stages (rs = ‐0.447, p<.001). The CIS sign was not associated with the presence of LBD (t(53) = 1.01, p = 0.319). Both the IMT (t(53) = ‐2.25, p = .028) and IMT/FSO (t(53) = ‐3.40, p = .001) ratios were associated with the presence of LATE‐NC.Conclusion: Co‐pathologies make a relatively small contribution to hypometabolism in patients with intermediate‐high ADNC. Novel biomarkers are needed for precise detection of co‐pathologies.

  • Open Access

    Tracing the spatial extent of cortical tau over time in Alzheimer’s disease

    by Frederic St‐Onge, Alexa Pichet Binette, Marianne Chapleau, John C.S. Breitner, Sylvia Villeneuve

    Background: Neuropathological studies defined the paradigm that tau—the pathological hallmark of Alzheimer’s disease (AD)—spreads homogenously across individuals from the medial temporal lobe to the neocortex. This staging system is referred to as Braak stages. However, neuroimaging studies have since highlighted significant inter‐regional and inter‐individual differences in tau spreading patterns. We investigated the spatial extent of cortical tau over time in the amnestic AD spectrum.Method: We included 195 amyloid‐positive ADNI participants that had at least two tau‐PET scans (90 cognitively unimpaired [CU], 66 with mild cognitive impairment [MCI], 39 with AD dementia; average follow‐up 2.6 years). We derived regional thresholds of tau positivity for 64 cortical regions and the amygdalae using Gaussian mixture modeling and applied them to all tau scans. The same approach was used to obtain thresholds for composite regions corresponding to the Braak stages. For each region, we calculated the rate of change in the amount (i.e., standardized uptake value ratio [SUVR] change) of tau pathology and the annual change in the positivity status (i.e., spatial extent change). These rates were compared between diagnostic groups using linear mixed models.Result: Across diagnostic groups, change in tau positivity followed Braak staging; over 90% of participants positive at follow‐up either progressed or were already positive on a previous Braak stage at baseline (Fig‐1AI) and greater SUVR change was observed in temporal regions (Fig‐1B). However, across the brain, there was heterogeneity between individual patterns of tau positivity progression (Fig‐1AII). This heterogeneity was most striking in MCI patients, where many regions progressed from low to high levels of tau (Fig‐1C). Regional SUVR change did not differ between participants with AD or with MCI (Fig‐2A), but participants with MCI showed the fastest change in regional positivity compared to participants with AD and CU participants. (Fig‐2B)Conclusion: While tau propagation follows Braak staging, inter‐individual differences can be found by considering a fine‐grained approach of regional progression to positivity. Furthermore, participants with MCI have the highest number of regions becoming abnormal annually. Our research pushes the importance of considering the entire brain when studying change in tau pathology, particularly before AD diagnosis.

  • Open Access

    Using data‐driven approaches to reveal distinct neurocognitive profiles in posterior cortical atrophy

    by Marianne Chapleau, Siddharth Ramanan, Renaud La Joie, Zachary Miller, Muireann Irish, Gil D. Rabinovici

    Background: Posterior cortical atrophy (PCA) is a clinically defined syndrome characterized by impairment in higher‐order visual processing due to neurodegeneration of posterior brain regions (occipito‐parietal and occipito‐temporal areas). Previous findings have reported broader cognitive impairment profiles, but their association with neural correlates remains unclear. In this project we aimed to use principal component analysis to explore the relationship between various cognitive dimensions and FDG‐PET hypometabolism in PCA patients.Method: We included 59 patients with a clinical diagnosis of PCA (with supporting radiological evidence) from the Memory and Aging Center database at the University of California in San Francisco (Table 1). The sample consisted of 64.4% females, mean age was 63.0 ± 7.6, and mean MMSE was 20.7 ± 5.6 at the diagnostic visit. Participants underwent extensive neuropsychological assessment; these scores were subsequently entered into an orthogonally‐rotated principal component analysis. In a subset of patients with FDG‐PET (N = 24), associations between the emergent cognitive components and whole‐brain hypometabolism were examined to explore neural correlates of cognitive heterogeneity.Result: Five components explained 72% of overall performance variation in PCA patients: episodic memory, visuospatial function, working memory, verbal generation, and naming/depression (Figure 1). Labels were assigned base on the primary area of greatest cognitive dysfunction. Visualization of component scores suggested systematic performance variation within the PCA sample. The mean metabolism map showed, as expected, predominant hypometabolism in occipito‐parietal and occipito‐temporal regions (Figure 2A). Voxel‐wise correlations revealed that hypometabolism in distinct frontoparietal regions underpinned episodic memory and visuospatial (inferior/superior parietal lobes), working memory and verbal generation (superior/middle frontal gyrus) performance (Figure 2B).Conclusion: PCA is a cognitively heterogeneous syndrome, where patients can show varying levels of cognitive deficits across episodic and working memory, executive functions, language and affect, over and above canonical visuospatial impairments.

  • Open Access

    Domain‐specific cognitive decline associates with differential regional tau burden in the Alzheimer’s disease spectrum

    by Frederic St‐Onge, Alexa Pichet Binette, Marianne Chapleau, John C.S. Breitner, Sylvia Villeneuve

    Background: Patients presenting with distinct clinical variants of Alzheimer’s disease (AD) present differential patterns of tau pathology measured with positron emission tomography (PET). Yet, a single set of brain regions like a temporal meta‐ROI is often chosen to study the association between cognition and tau. Instead, we aimed to map the associations between regional tau and multiple cognitive domains, and to test whether using whole brain information yields stronger associations with cognition compared to a singular composite region.Method: We included 372 amyloid‐positive ADNI participants that had at least one tau‐PET scan (163 cognitively unimpaired [CU], 132 with mild cognitive impairment [MCI], 77 with AD dementia). Composite cognitive scores for memory, executive functioning, visuospatial and language were used for cross‐sectional (closest score to tau‐PET) and longitudinal analyses. Individual rate of cognitive decline was computed using linear mixed effect models, leveraging all visits available for each participant. We did region‐wise analyses, relating tau in the 64 regions of the Desikan‐Killiany atlas plus the amygdalae with cognitive performance and rate of cognitive decline. We also derived a “spatial extent index” where we computed the number of abnormal tau regions and compared the performance of this index to detect cognitive impairment to what would have been found with a classical temporal meta‐ROI SUVR value.Result: No regional association between tau and cognition survived FDR correction in CU participants. Cross‐sectionally and longitudinally, participants with MCI and with AD dementia, associations between tau and memory were predominant in the temporal lobe, associations with language were restricted mostly to the left hemisphere and associations with executive functioning spanned the entire cortex. (Fig 1) Comparing the sum of tau positive regions (spatial extent index) to tau SUVR in the temporal meta‐ROI, both measures were similarly associated with cognition, except for executive functioning at baseline where the spatial extent index was more strongly associated with cognition than the meta‐ROI. (Fig 2)Conclusion: While temporal meta‐ROI tau SUVR may be sufficient to track non‐executive cognitive performance in individual with cognitive impairments, a whole brain measure may provide additional information regarding executive impairment occurring in AD.

  • Open Access

    Domain‐specific cognitive decline associates with differential regional tau burden in the Alzheimer’s disease spectrum

    by Frederic St‐Onge, Alexa Pichet Binette, Marianne Chapleau, John C.S. Breitner, Sylvia Villeneuve

    Background: Patients presenting with distinct clinical variants of Alzheimer’s disease (AD) present differential patterns of tau pathology measured with positron emission tomography (PET). Yet, a single set of brain regions like a temporal meta‐ROI is often chosen to study the association between cognition and tau. Instead, we aimed to map the associations between regional tau and multiple cognitive domains, and to test whether using whole brain information yields stronger associations with cognition compared to a singular composite region.Method: We included 372 amyloid‐positive ADNI participants that had at least one tau‐PET scan (163 cognitively unimpaired [CU], 132 with mild cognitive impairment [MCI], 77 with AD dementia). Composite cognitive scores for memory, executive functioning, visuospatial and language were used for cross‐sectional (closest score to tau‐PET) and longitudinal analyses. Individual rate of cognitive decline was computed using linear mixed effect models, leveraging all visits available for each participant. We did region‐wise analyses, relating tau in the 64 regions of the Desikan‐Killiany atlas plus the amygdalae with cognitive performance and rate of cognitive decline. We also derived a “spatial extent index” where we computed the number of abnormal tau regions and compared the performance of this index to detect cognitive impairment to what would have been found with a classical temporal meta‐ROI SUVR value.Result: No regional association between tau and cognition survived FDR correction in CU participants. Cross‐sectionally and longitudinally, participants with MCI and with AD dementia, associations between tau and memory were predominant in the temporal lobe, associations with language were restricted mostly to the left hemisphere and associations with executive functioning spanned the entire cortex. (Fig 1) Comparing the sum of tau positive regions (spatial extent index) to tau SUVR in the temporal meta‐ROI, both measures were similarly associated with cognition, except for executive functioning at baseline where the spatial extent index was more strongly associated with cognition than the meta‐ROI. (Fig 2)Conclusion: While temporal meta‐ROI tau SUVR may be sufficient to track non‐executive cognitive performance in individual with cognitive impairments, a whole brain measure may provide additional information regarding executive impairment occurring in AD.

  • Open Access

    Tracing the spatial extent of cortical tau over time in Alzheimer’s disease

    by Frederic St‐Onge, Alexa Pichet Binette, Marianne Chapleau, John C.S. Breitner, Sylvia Villeneuve

    Background: Neuropathological studies defined the paradigm that tau—the pathological hallmark of Alzheimer’s disease (AD)—spreads homogenously across individuals from the medial temporal lobe to the neocortex. This staging system is referred to as Braak stages. However, neuroimaging studies have since highlighted significant inter‐regional and inter‐individual differences in tau spreading patterns. We investigated the spatial extent of cortical tau over time in the amnestic AD spectrum.Method: We included 195 amyloid‐positive ADNI participants that had at least two tau‐PET scans (90 cognitively unimpaired [CU], 66 with mild cognitive impairment [MCI], 39 with AD dementia; average follow‐up 2.6 years). We derived regional thresholds of tau positivity for 64 cortical regions and the amygdalae using Gaussian mixture modeling and applied them to all tau scans. The same approach was used to obtain thresholds for composite regions corresponding to the Braak stages. For each region, we calculated the rate of change in the amount (i.e., standardized uptake value ratio [SUVR] change) of tau pathology and the annual change in the positivity status (i.e., spatial extent change). These rates were compared between diagnostic groups using linear mixed models.Result: Across diagnostic groups, change in tau positivity followed Braak staging; over 90% of participants positive at follow‐up either progressed or were already positive on a previous Braak stage at baseline (Fig‐1AI) and greater SUVR change was observed in temporal regions (Fig‐1B). However, across the brain, there was heterogeneity between individual patterns of tau positivity progression (Fig‐1AII). This heterogeneity was most striking in MCI patients, where many regions progressed from low to high levels of tau (Fig‐1C). Regional SUVR change did not differ between participants with AD or with MCI (Fig‐2A), but participants with MCI showed the fastest change in regional positivity compared to participants with AD and CU participants. (Fig‐2B)Conclusion: While tau propagation follows Braak staging, inter‐individual differences can be found by considering a fine‐grained approach of regional progression to positivity. Furthermore, participants with MCI have the highest number of regions becoming abnormal annually. Our research pushes the importance of considering the entire brain when studying change in tau pathology, particularly before AD diagnosis.

  • Open Access

    Association of FDG‐PET with co‐pathologies in autopsy‐proven AD

    by Marianne Chapleau, Nidhi Mundada, Salvatore Spina, William W. Seeley, Lea T. Grinberg, Daniel Schonhaut, Howard J. Rosen, Joel H. Kramer, Bruce L Miller, Renaud La Joie, et al.

    Background: The presence of multiple pathologies is the rule and not the exception in Alzheimer’s disease (AD). The goal of this study was to assess whether 18F fluorodeoxyglucose (FDG) PET can provide information about the presence of non‐AD pathologies in autopsy‐proven AD patients.Method: Our cohort included 55 patients with antemortem FDG‐PET and autopsy‐proven intermediate/high ADNC from the UCSF Neurodegenerative Diseases Brain Bank. All patients underwent FDG‐PET. Standardized uptake value ratio (SUVR) images were computed using the pons as reference region. W‐maps (adjusted Z‐score maps) were created, comparing each patient to a group of 187 controls (age range: 20‐96, 40% males). Voxel‐wise correlations were computed to verify the unique contribution of each neuropathology to cerebral hypometabolism, while controlling for age, sex, time between FDG‐PET scan and death, scanner type, Thal and Braak staging, and the presence of all other co‐pathologies. Associations between SUVR values in specific region of interests (ROIs) were also assessed. The ROIs included were the following: Landau AD ROI for AD pathology, Cingulate Island Sign (CIS) for Lewy body disease, Inferior/Medial Temporal Lobe (IMT) and IMT/Frontal Supraorbital (IMT/FSO) ratios for limbic‐predominant age‐related TDP43 encephalopathy neuropathologic change (LATE‐NC).Result: Mean age was 63.8 ± 10.5, mean time between FDG and death was 6.2 ± 2.8, and mean MMSE was 21.1 ± 7.1 at the time of PET (Table 1). Group averaged W‐map showed the typical temporo‐parietal AD pattern; hypometabolism in these regions was associated with higher Thal phase and Braak stage (Figure 1). Lewy body disease (LBD), argyrophilic grain disease (AGD), aging‐related tau astrogliopathy (ARTAG), cerebral amyloid angiopathy (CAA) and vascular brain injury (VBI) were associated with hypometabolism in small discrete regional clusters (Figure 2). The Landau AD ROI was associated with both Thal (rs = ‐0.325, p = .015) and Braak stages (rs = ‐0.447, p<.001). The CIS sign was not associated with the presence of LBD (t(53) = 1.01, p = 0.319). Both the IMT (t(53) = ‐2.25, p = .028) and IMT/FSO (t(53) = ‐3.40, p = .001) ratios were associated with the presence of LATE‐NC.Conclusion: Co‐pathologies make a relatively small contribution to hypometabolism in patients with intermediate‐high ADNC. Novel biomarkers are needed for precise detection of co‐pathologies.

  • Open Access

    Correction to: Diagnosis and Management of Posterior Cortical Atrophy

    by Keir X. X. Yong, Jonathan Graff‑Radford, Samrah Ahmed, Marianne Chapleau, Rik Ossenkoppele, Deepti Putcha, Gil D. Rabinovici, Aida Suarez‑Gonzalez, Jonathan M. Schott, Sebastian Crutch, et al.

  • Open Access

    Trait mindfulness is associated with less amyloid, tau, and cognitive decline in individuals at risk for Alzheimer’s disease

    by Cherie Strikwerda-Brown, Hazal Ozlen, Alexa Pichet Binette, Marianne Chapleau, Natalie L. Marchant, John C. S. Breitner, Sylvia Villeneuve

    BACKGROUND AND OBJECTIVES: Mindfulness, defined as non-judgmental awareness of the present moment, has been associated with an array of mental and physical health benefits, including improved cognitive functioning and changes to brain structure and function. Mindfulness may also represent a protective factor for Alzheimer’s disease (AD). Here, we tested the potential protective effect of trait mindfulness on cognitive decline and AD pathology in older adults at risk for AD dementia. METHODS: Two hundred sixty-one nondemented older adults with a family history of AD dementia were included from the PREVENT-AD observational cohort study, including 124 with Aβ- and tau-positron emission tomography (PET) scans. All participants completed measures of trait mindfulness and longitudinal cognitive assessments. Multivariate partial least squares analyses were used to examine relationships between combinations of different facets of trait mindfulness and (1) cognitive decline, (2) Aβ, and (3) tau. RESULTS: Higher levels of mindful nonjudgment, describing, and nonreactivity were associated with less cognitive decline in attention, global cognition, and immediate and delayed memory. Higher levels of mindful nonjudgment and nonreactivity were related to less Aβ-PET signal in bilateral medial and lateral temporoparietal and frontal regions. Higher levels of mindful acting with awareness, describing, nonjudgment, and nonreactivity were associated with less tau-PET signal in bilateral temporal regions, namely entorhinal cortex, amygdala, and parahippocampal, fusiform, and inferior temporal gyri. These relationships remained significant when additional demographic (age, sex, education and APOE status) and psychological (personality traits and neuropsychiatric symptoms) were included in analyses. When mindfulness, personality traits, and neuropsychiatric symptoms were entered into the same model, mindful nonjudgment showed the strongest association with cognitive decline and Aβ. DISCUSSION: Trait mindfulness is associated with less cognitive decline and less Aβ and tau in the brain in older adults at risk for AD dementia. In addition to its other health benefits, trait mindfulness may also represent a psychological protective factor for AD dementia. Longitudinal studies examining the temporal relationship between trait mindfulness and AD markers, along with mindfulness intervention studies with cognition and pathology as outcome variables, will be important for further clarifying the potential protective benefits of mindfulness on AD risk.

  • The role of the hippocampus in the semantic variant of primary progressive aphasia: A resting‐state fcMRI study

    by Marianne Chapleau, Maxime Montembeault, Mariem Boukadi, Christophe Bedetti, Robert Laforce, Maximiliano Wilson, Simona M. Brambati

    The goal of the study was to determine whether the semantic variant of primary progressive aphasia (svPPA) affects the intrinsic connectivity network anchored to left and right anterior hippocampus, but spares the posterior hippocampus. A resting‐state functional connectivity MRI (rs‐fcMRI) study was conducted in a group of patients with svPPA and in controls, using a seed‐to‐voxel approach. In comparison to controls, massively reduced connectivity was found in the anterior hippocampus, mainly the left one, for svPPA patients but not in the left or right posterior hippocampus. In svPPA, the anterior hippocampus showed reduced functional connectivity with regions implicated in the semantic memory network. Significant correlation was also found between the functional connectivity strength of the left anterior hippocampus and the ventromedial cortex, and performance in semantic tasks. These findings indicate that the functional disconnection of the anterior hippocampus may be a promising in vivo biomarker of svPPA and illustrate the role of this hippocampal subregion in the semantic memory system.